Remote Hemodynamic Monitoring for High-Risk Chronic Heart Failure

The jury is still out.

The efficacy of implantable remote hemodynamic monitoring as a means of guiding pharmacotherapy in patients with heart failure (HF) remains unclear despite two previously published randomized trials, which provided inconsistent results. Current American College of Cardiology/American Heart Association HF guidelines include a weak (IIb) recommendation for consideration of remote hemodynamic monitoring in patients with HF and New York Heart Association (NYHA) class III symptoms despite optimal medical and device therapy.

The manufacturer-funded, open-label MONITOR-HF trial (NTR7672), conducted in the Netherlands, enrolled 348 individuals with NYHA class III symptoms and a previous hospitalization for HF (median age, 69 years; median left ventr…

Reviewing Author

Frederick A. Masoudi, MD, MSPH, MACC, FAHA

Disclosures

Consultant/Advisory BoardBristol Myers Squibb; CPC Clinical Research

Grant/Research SupportNational Heart, Lung, and Blood Institute

Editorial BoardsUpToDate; American College of Cardiology Self-Assessment Program (SAP)

Leadership Positions in Professional SocietiesAmerican College of Cardiology (Chair, Innovations Committee)